Category Archives: Stem Cell Therapy

About Lonza

At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.

We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.

Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more atwww.lonza.comand follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.

About FUJIFILM

FUJIFILM Cellular Dynamics, Inc. (FCDI) is a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) utilized in drug discovery and cell therapies. FCDI is using its expertise in iPSC technologies to develop a robust cell therapeutics pipeline to address unmet medical needs in areas such as age-related macular degeneration, retinitis pigmentosa and immuno-oncology. For its partners, FCDI utilizes its iPSC platform to advance the progress of therapeutic candidates in the clinic and provides contract development and manufacturing (CDMO) services. In addition to cell therapy, FCDI also offers life science research tools including the companys inventoried iCell products, which are available in almost any cell type and are sourced from multiple cell lines which can be applied for target identification as well as toxicity testing. The company also offers custom cell development services and cell banking. FCDIs goal is to leverage the vast utility of iPSCs to advance human health and improve the quality of life for patients around the world. For more information, please visit:https://fujifilmcdi.com

FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document and imaging products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit:www.fujifilmholdings.com

Lonza Contact Details

FUJIFILM Contact Details:

Christine Jackman

FUJIFILM

(914) 789-8523

christine.jackman@fujfilm.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (SGX-ST). Lonza Group Ltd is not subject to the SGX-STs continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this newsrelease. All product and company names herein may be trademarks of their registered owners.

Visit link:
FUJIFILM Cellular Dynamics and Lonza Agree to Expand the Availability and Use of Induced Pluripotent Stem Cell Technology - BioSpace

Background 18-F fluorodeoxyglucose (FDG) uptake in the liver was used as a reference to characterize a complete molecular response (CMR) using positron emission tomography/computed tomography imaging (PET/CT) in patients undergoing treatment for newly diagnosed multiple myeloma, according to findings published in the Journal of Clinical Oncology.1

In order to determine response to treatment in the setting of multiple myeloma, the bone marrow (BM) needs to be assessed and the presence of any extramedullary disease (EMD) needs to detected. While FDG-PET/CT has become the preferred imaging method for the detection of minimal residual disease (MRD) in both of these compartments following treatment, and is considered complementary to the use of flow cytometry for identifying MRD in the bone marrow, standardized FDG-PET/CT criteria are needed to define CMR after therapy.

To date, few indications to interpret FDG-PET/CT after therapy have been proposed or validated, the study investigators noted.

This study relied on data from imaging substudies of 2 randomized, open-label, multicenter, phase 3 clinical trials of 228 transplant-eligible patients with newly diagnosed multiple myeloma treated with modern-era regimens in which at least 1 arm of each study also underwent autologous stem cell transplantation (ASCT).2,3

Whole-body PET/CT, including skull, upper limbs, and femurs, was performed at diagnosis, after induction therapy, and at completion of treatment but prior to maintenance therapy, if administered.

In particular, BM metabolic state, focal lesions (FLs; number and metabolic state), and EMD (site, number, and metabolic state) were checked and reported. FDG uptake degree was visually quantied in the target lesion according to the 5-point Deauville scale (DS) adopted for PET scans in lymphomas (FL score [FS]) and in the BM out of FLs (BM score [BMS]), the study authors clarified. Semiquantitative measures of FDG uptake by the liver and mediastinal blood pool were also determined.

The primary objectives of these imaging substudies were to dene criteria for PET CMR after therapy (PET MRD denition) by testing the prognostic impact of such criteria on [progression-free survival (PFS)]. A secondary objective was to assess whether these criteria were associated with overall survival (OS).

A key finding of this study was that, compared with a FS and a BMS of 4 or higher, a FS and a BMS less than 4, which was lower than the DS score for the liver, were independently associated with prolonged PFS on multivariate analysis (FS: hazard ratio [HR], 0.60; 95% CI, 0.37-0.95; P =.030; BMS: HR, 0.50; 95% CI, 0.26-0.97; P =.041).

In addition, on multivariate analysis, FS and BMS less than 4 were also independent predictors of prolonged OS (FS: HR, 0.34; 95% CI, 0.16-0.70; P =.004; BMS: HR, 0.25; 95% CI, 0.10-0.66; P =.005).

On the basis of these results, we believe that reduction of FL and BM uptake lower than the liver (DS score below 4) can be proposed as the standardized denition of PET CMR after therapy within new PET response criteria, the study investigators stated.

Nevertheless, they cautioned that prospective clinical trials are needed to validate these results, and to evaluate whether there is concordance between CMR as determined by FDG-PET/CT and MRD in the bone marrow by flow cytometry.

References

Originally posted here:
Toward the Development of Standardized FDG-PET Imaging Criteria to Characterize Response in Multiple Myeloma - Cancer Therapy Advisor

Researchers discuss the development and potential of stem cellbased therapies in the treatment of Parkinson disease.

In assessing treatment for Parkinson disease (PD), the current standard of care involves levodopa, potentially in combination with carbidopa, to address the loss of dopamine known to occur as the condition progresses. However, several innovations in therapy for PD have occurred in recent years, particularly deep brain stimulation and the potential use of stem cells.

Discussing in a review published in International Journal of Molecular Sciences, researchers Zhaohui Liu, PhD, MSc, and Hoi-Hung Cheung, PhD, sought to discuss the development of new therapeutic strategies that have led to the initiation of exploratory clinical trials, particularly the application of stem cells for the treatment of PD.

Delving into the use of stem cellbased treatments in PD, the researchers say that several important pathways have emerged as targets for potential therapeutic intervention.

Conventional therapeutic strategies for relieving the symptomatic stages of PD remain, but with new genetic insights, it may be possible to use preventive neuroprotective treatments for people at risk of developing PD, they highlight. In parallel with efforts to prevent and control symptomatic PD, researchers are also investigating stem cells as replacements for diseased neurons or degenerated tissues.

As they note, dopaminergic (DA) cell transplantation is believed to be the most promising cell replacement therapy. Aligned with this approach, a recent novel treatment showcased the plausibility of reprogramming the skin cells of a single patient with PD to take on the characteristics of DA neurons and replace damaged brain cells. In their findings, the patient exhibited improvements in quality of life and day-to-day activities requiring motor skills. However, as this treatment was performed on only 1 person, the researchers cautioned that larger, diverse clinical studies are needed to demonstrate further efficacy and long-term results.

Other notable stem cellbased treatments include:

Although we are not yet examining a disease-modifying treatment, stem cell transplantation has the potential to be at the forefront of such PD treatments in the future, conclude the researchers. The transplantation process and the procedures required for its optimization are still not fully understood, and further research is required to achieve treatment for PD.

Reference

Liu Z, Cheung H-H. Stem cell-based therapies for Parkinson disease. Int J Mol Sci. Published online October 29, 2020. doi:10.3390/ijms21218060

Read more:
A Review of Stem Cell-Based Therapies for Parkinson Disease - AJMC.com Managed Markets Network

Retinal Disorders Treatment Market: Introduction

According to the report, the global retinal disorders treatment market was valued at US$ 9.18 Bn in 2019 and is projected to expand at a CAGR of ~7% from 2020 to 2030. Macular degeneration is of two types: wet age-related macular degeneration and dry age-related macular degeneration. Diabetic retinopathy is one of the common diabetic eye disorders characterized by damaged blood vessels in the retina. Damaged blood vessels and nerves lead to vision impairment, blurring of vision, and eye hemorrhage. If left untreated, it could lead to retinal detachment and blindness. In terms of indication, the global retinal disorders treatment market has been classified into macular degeneration, diabetic retinopathy, diabetic macular edema, and others. The macular degeneration segment has been bifurcated into dry macular degeneration and wet macular degeneration. Based on therapeutic class, the global retinal disorders treatment market has been categorized into anti-VEGF agents and others. In terms of dosage form, the global retinal disorders treatment market has been divided into gels, eye solutions, capsules & tablets, eye drops, and ointments.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79712

Based on distribution channel, the global retinal disorders treatment market has been segregated into hospital pharmacies, retail pharmacies, and online sales. Rise in prevalence of retinal disorders due to increase in geriatric patient population boosts the growth of the global retinal disorders treatment market. The U.S. dominated the global retinal disorders treatment market in 2019, and the trend is anticipated to continue during the forecast period. Well-established healthcare infrastructure and early adoption of advanced technologies are the factors expected to fuel the growth of the market in the region. Moreover, rise in prevalence of various types of retinal disorder leads to increase in demand for treatment.

China is likely to be a highly lucrative market for retinal disorders treatment during the forecast period. Diagnosis and treatment rates have increased due to a rise in disposable income and health awareness. This has led to an increase in the adoption of macular degeneration drugs

Rise in Prevalence of Retinal Disorders Due to Increase in Geriatric Patient Population to Drive Global Market

Age is a prominent risk factor for age-related macular degeneration. The risk of developing advanced age-related macular degeneration increases from 2% in people aged between 50 and 59 to nearly 30% for those over 75. The prevalence of other retinal disorders was 93 million people with diabetic retinopathy, 21 million people diabetic macular edema and 28 million people with vision-threatening diabetic retinopathy. Increase in R&D activities, rise in the number of patients suffering from diseases, and rapid expansion of healthcare and biopharmaceutical industries in developed and developing countries are projected to boost advancements in therapies in the AMD treatment market during the forecast period. For instance, Lucentis and Eylea accounted for 2.8% of total pharmaceutical sales in Canada in 2017.

Request for Analysis of COVID-19 Impact on Retinal Disorders Treatment Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=79712

Macular Degeneration to Dominate Global Market

In terms of indication, the global retinal disorders treatment market has been divided into macular degeneration, diabetic retinopathy, diabetic macular edema, and others. Macular degeneration has been bifurcated into dry macular degeneration and wet macular degeneration. The macular degeneration segment dominated the market in terms of revenue in 2019. The rise in prevalence of macular degeneration is anticipated to drive the segment during the forecast period. For instance, the number of people living with macular degeneration is expected to reach 196 million globally by 2020 and increase to 288 million by 2040.

Anti-VEGF Agents to be Main Therapeutic Class

Based on therapeutic class, the global retinal disorders treatment market has been categorized into anti-VEGF agents and others. The anti-VEGF agents dominated the global retinal disorders treatment market in 2019. Major market products such as Avastin and Eylea are included in the anti-VEGF drug class. Increase in demand for these products in the treatment of retinal disorders and strong product pipeline are likely to drive the segment. However, the others segment, which includes anti-inflammatory drugs, is projected to expand at the highest CAGR from 2020 to 2030. The increase in the use of anti-inflammatory drugs for pain relief is anticipated to augment the segment.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=79712

Eye Solutions to be Preferred Dosage Form

In terms of dosage form, the global retinal disorders treatment market has been divided into gels, eye solutions, capsules & tablets, eye drops, and ointments. The eye solutions segment dominated the global retinal disorders treatment market in 2019. However, the eye drops segment is expected to expand at the highest CAGR during the forecast period. The segment is likely to grow at a rapid pace due to increase in demand for eye drops for treatment of retinal diseases in emerging countries such have China, India, and Brazil.

Retail Pharmacies to Emerge as Major Distribution Channel

Based on distribution channel, the global retinal disorders treatment market has been segregated into hospital pharmacies, retail pharmacies, and online sales. The retail pharmacies segment dominated the market in terms of revenue in 2019 due to wide network, ease of access, and diverse product offerings, including prescription and OTC ophthalmic drugs. However, the shift toward the use of electronic payment modes is projected to boost the growth of the online sale segment during the forecast period.

U.S. to Dominate Global Market

The global retinal disorders treatment market has been segmented into five major regions/country: the U.S., Europe, China, Russia, and Rest of the World. The U.S. dominated the global market in 2019, followed by Europe. The U.S. accounted for a major share of the global retinal disorders treatment market in 2019. Well-developed healthcare infrastructure, high healthcare expenditure, and adoption of branded drugs to treat retinal disorder disorders are the key factors attributed to the countrys significant share of the global market.

The retinal disorders treatment market in China is anticipated to expand at a high CAGR from 2020 to 2030. There have been significant unmet medical needs in the region. Furthermore, healthcare expenditure is increasing in developing markets. Key players are making investments to establish their operations in China. This, in turn, is projected to augment the market in the country.

Buy Retinal Disorders Treatment Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=79712&ltype=S

Competition Landscape

Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., and Novartis AG are the three major companies operating in the global retinal disorders treatment market. The global retinal disorders treatment market is fragmented in terms of number of players. Key players in the global market include Allergan plc, Bayer AG, F. Hoffmann-La Roche Ltd., Graybug Vision, Inc., Kubota Pharmaceutical Holdings Co., Ltd., Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited. New product development through robust R&D activities and mergers & acquisitions are key strategies adopted by these players to gain a competitive advantage in the global retinal disorders treatment market.

Browse More Trending Reports by Transparency Market Research:

Lumbar Stenosis Treatment Market: https://www.transparencymarketresearch.com/lumbar-stenosis-treatment-market.html

Intracranial Stenosis Treatment Market: https://www.transparencymarketresearch.com/intracranial-stenosis-treatment-market.html

Plastic Bandages Market: https://www.transparencymarketresearch.com/plastic-bandages-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Visit link:
Retinal Disorders Treatment Market: Advancements in Gene-therapy and Stem-cell Therapy to Bolster Market Growth - BioSpace

Global Canine Stem Cell Therapy Market report provides in-depth analysis and detailed information by key players, end-users, applications, Competitor analysis, geography, Sales, Revenue, Price, Gross Margin, Market Share, Import-Export, Trends, CAGR value and how it is expected to reach from 2020 to 2026.

Global Canine Stem Cell Therapy Market Report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Canine Stem Cell Therapy market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

The global Canine Stem Cell Therapy market was valued at US$ 118.5 Mn in 2018 and is expected to reach US$ 240.7 Mn in 2026, growing at a CAGR of 9.3% during the forecast period.

Request for Sample Copy of Canine Stem Cell Therapy market Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.alltheresearch.com/sample-request/206

The report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out.

Key Players covered in this Canine Stem Cell Therapy market report are

The report splits by major applications:

Then report analyzed by types:

Any questions, Lets discuss with the analyst @ https://www.alltheresearch.com/speak-to-analyst/206

The Study Objectives Are:

The Canine Stem Cell Therapy industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed, and overall research conclusions offered.

With the tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

The Canine Stem Cell Therapy Market report provides key statistics on the market status of the Canine Stem Cell Therapy manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Get Brief Information on Pre COVID-19 Analysis and Post COVID-19 Opportunities in Canine Stem Cell Therapy Market at https://www.alltheresearch.com/impactC19-request/206

How Report will help you to make decisions for business:

About AllTheResearch:

AllTheResearch was formed with the aim of making market research a significant tool for managing breakthroughs in the industry. As a leading market research provider, the firm empowers its global clients with business-critical research solutions. The outcome of our study of numerous companies that rely on market research and consulting data for their decision-making made us realise, that its not just sheer data-points, but the right analysis that creates a difference. While some clients were unhappy with the inconsistencies and inaccuracies of data, others expressed concerns over the experience in dealing with the research-firm. Also, same-data-for-all-business roles was making research redundant. We identified these gaps and built AllTheResearch to raise the standards of research support.

For All Your Research Needs, Reach Out us at:

Contact Name: Rohan S.

Email: [emailprotected]

Phone: +1 (407) 768-2028

See the article here:
Canine Stem Cell Therapy Market Shows Expected Trend to Guide from 2020-2026 with Growth Analysis by Manufacturers, Regions, Type and Application -...

The Global Stem Cell Therapy Market report, published by Verified Market Research, is an extensive compilation of the essential aspects of the global Stem Cell Therapy market, assessed thoroughly by our team of researchers. The market intelligence report offers insightful data and information relevant to the market to acquaint the readers with the lucrative growth prospects existing in this industry, eventually helping them formulate effective business strategies. The global Stem Cell Therapy market report has been methodically curated using industry-verified data to offer information concerned with the leading manufacturers and suppliers engaged in this sector. It further focuses on their pricing analysis, gross revenue, product portfolio, sales network & distribution channels, profit margins, and financial standing.

Global Stem Cell Therapy Market was valued at USD 117.66 million in 2019 and is projected to reach USD 255.37 million by 2027, growing at a CAGR of 10.97% from 2020 to 2027.

The global Stem Cell Therapy market is highly consolidated due to the presence of a large number of companies across this industry. The report discusses the current market standing of these companies, their past performances, demand and supply graphs, production and consumption patterns, sales network, distribution channels, and growth opportunities in the market. Moreover, it highlights the strategic approaches of the key players towards expanding their product offerings and reinforcing their market presence.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

The report further sheds light on the various strategic business initiatives undertaken by the key market contenders to fortify their foothold in this business sector. These strategies majorly include mergers & acquisitions, partnerships & collaborations, joint ventures, government and corporate deals, brand promotions, new product launches, and numerous others. In the later part of the report, the major components of the Stem Cell Therapy industry, such as product type, application gamut, end-use industries, and the solutions and services offered by the leading manufacturers, have been analyzed. Numerical data and subjective information pertaining to each market segment have been featured in the report for better understanding.

Therefore, the latest research document includes competitive analysis, key market players, crucial industry-related facts & figures, sales revenue, product prices, gross margins, market shares, business strategies, dominant regions, and key developments.

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

Request a discount on the report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113

The report encompasses the significant effects of the coronavirus pandemic on the Stem Cell Therapy market and its key segments. The report offers a vivid picture of the current market scenario, closely investigating the impact of the pandemic on this specific business sphere, its leading players, supply chains, distribution channels, and its global scenario. The pandemic has affected the global industry extensively, subsequently disrupting the Stem Cell Therapy market mechanism. Furthermore, the research study examines the Stem Cell Therapy market and the recent disruptive changes in the business setting that followed the outbreak. Also, the future effects of the pandemic on the market have been assessed in the report.

Key Geographies Encompassed in the Report:

North America (U.S., Canada)Europe (U.K., Germany, Italy, France, Rest of EU)Asia Pacific (India, Japan, China, Australia, Rest of APAC)Latin America (Brazil, Argentina, Rest of Latin America)Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Market Taxonomy:

Chapter 1: Methodology & Scope

Definition and forecast parametersMethodology and forecast parametersData Sources

Chapter 2: Executive Summary

Business trendsRegional trendsProduct trends

Chapter 3: Industry Insights

Industry segmentationIndustry landscapeVendor matrixTechnological and innovation landscape

Chapter 4: Regional Landscape

Chapter 5: Competitive Outlook

Company ProfileBusiness OverviewFinancial DataProduct LandscapeStrategic Outlook

To read more about the report, visit @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/

Advantages of the Stem Cell Therapy Market Report:

The report offers a clear description of the global Stem Cell Therapy market, containing the current market growth inclinations and future estimations to help businesses identify the potential investment areas.

The report covers the major market growth drivers, and constraints, alongside an extensive COVID-19 impact analysis.

The all-inclusive market feasibility reveals the profit-making trends to obtain a powerful foothold in the Stem Cell Therapy industry.

The SWOT analysis and Porters Five Forces Analysis explicate the effectiveness of the customers and providers from a global perspective.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Continue reading here:
Stem Cell Therapy Market To Exceed Revenues Worth US$ By The End Of 2020 2027 - Eurowire